Cargando…

Megamitochondria formation in hepatocytes of patient with chronic hepatitis C – a case report

Although chronic hepatitis C virus (HCV) infection affect 185 million people world-wide, pathomechanism of liver damage is still unclear. Electron microscopy can reveal liver injury in very early stage and help understanding the mechanisms that is crucial in the pathogenesis of chronic hepatitis C....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wieczorek, Anna, Stępień, Piotr M., Zarębska-Michaluk, Dorota, Kryczka, Wiesław, Pabjan, Paweł, Król, Teodora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649480/ https://www.ncbi.nlm.nih.gov/pubmed/29062908 http://dx.doi.org/10.5114/ceh.2017.68287

Ejemplares similares

Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
por: Stępień, Piotr M., et al.
Publicado: (2015)

Retreatment of symptomatic hepatitis C virus genotype 3 associated mixed cryoglobulinemia with sofosbuvir and ribavirin: a case report
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2018)

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2016)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
por: Pabjan, Paweł, et al.
Publicado: (2022)

Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver
por: Yamada, Tatsuya, et al.
Publicado: (2022)

Viral hepatitis C treatment shortening – what is the limit?
por: Zarębska-Michaluk, Dorota
Publicado: (2019)

Genotype 3-hepatitis C virus’ last line of defense
por: Zarębska-Michaluk, Dorota
Publicado: (2021)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

The Effect of Reduced Oxygen Saturation on Retinal Microvascularization in COVID-19 Patients with Bilateral Pneumonia Based on Optical Coherence Tomography Study
por: Kal, Magdalena, et al.
Publicado: (2022)

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study
por: Janczewska, Ewa, et al.
Publicado: (2015)

Long-Term Effect of SARS-CoV-2 Infection on the Retinal and Choroidal Microvasculature
por: Kal, Magdalena, et al.
Publicado: (2023)

Retinal Microvascular Changes in COVID-19 Bilateral Pneumonia Based on Optical Coherence Tomography Angiography
por: Kal, Magdalena, et al.
Publicado: (2022)

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Trends of infections and mortality due to hepatitis B virus (2005-2022) and the potential impact of the COVID-19 pandemic: a population-based study in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Obligation Is Not a Compulsion—The Quality of the Law and the Effectiveness and Safety of Vaccination against COVID-19
por: Kocańda, Kamila, et al.
Publicado: (2022)

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Reduced Vessel Density and Enlarged Foveal Avascular Zone in the Macula as a Result of Systemic Hypoxia Caused by SARS-CoV-2 Infection
por: Kal, Magdalena, et al.
Publicado: (2023)

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study
por: Simon, Krzysztof Adam, et al.
Publicado: (2019)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Global Elimination of HCV—Why Is Poland Still So Far from the Goal?
por: Tronina, Olga, et al.
Publicado: (2023)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

How close are we to hepatitis C virus elimination in Central Europe?
por: Flisiak, Robert, et al.
Publicado: (2020)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19
por: Łysek-Gładysińska, Małgorzata, et al.
Publicado: (2023)

Hepatitis C virus entry into the hepatocyte
por: Belouzard, Sandrine, et al.
Publicado: (2011)

Cytokine profile and viral diversity in the early seronegative stage of community-acquired hepatitis C virus (HCV) infection
por: Radkowski, Marek, et al.
Publicado: (2023)

Association of Hepcidin mRNA Expression With Hepatocyte Iron Accumulation and Effects of Antiviral Therapy in Chronic Hepatitis C Infection
por: Sikorska, Katarzyna, et al.
Publicado: (2014)

Regulated Entry of Hepatitis C Virus into Hepatocytes
por: Miao, Zhijiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_214re2in7mgk5ggaq76rgfvgm8